ImmuCell Swings to $953K Profit as Q3 Revenue Jumps 46% to $8.0M
ICCC has more than doubled off its 52-week low of $4.52.
Summary
ImmuCell posted Q3 revenue of $8.0M, up 46% year over year, and net income of $953K — a $1.1M improvement from a year ago. Gross margin came in at 44.2%, up 130 basis points, helped by higher pricing and better manufacturing execution. The top line got an assist from an easier comparison: last year's Q3 was dented by distributor destocking, though out-the-door volume still grew 18%, so the underlying demand is real. Two balance-sheet items matter here: the company terminated its at-the-market offering, removing a dilution overhang, and it expects to sign a new $3M credit line in Q4 2026. This follows the October 12 preliminary sales release and the October 13 8-K that attached it — the new information is the profit, margin and financing detail. Watch whether the $3M credit line actually gets signed in Q4, and whether the capacity expansion and colostrum-sourcing spend start showing up in margins.
At the time of this announcement, ICCC was trading at $10.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $92.8M. The 52-week trading range was $4.52 to $12.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.